{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:04Z","timestamp":1786979884615,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00259-017-3759-4","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:36:13Z","timestamp":1498178173000},"page":"2004-2013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Diagnostic utility of PET\/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-5293","authenticated-orcid":false,"given":"Ana Reyes","family":"Romero-Lluch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Cuenca-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Guerrero-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Jes\u00fas","family":"Mart\u00ednez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Tirado-Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Borrego-Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"issue":"6","key":"3759_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised american thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610. doi:\n10.1089\/thy.2014.0335\n\n.","journal-title":"Thyroid"},{"issue":"2","key":"3759_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ecl.2014.02.004","volume":"43","author":"MI Hu","year":"2014","unstructured":"Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014;43(2):423\u201342. doi:\n10.1016\/j.ecl.2014.02.004\n\n.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"3759_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","volume":"40","author":"S Balogova","year":"2013","unstructured":"Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40(6):943\u201366. doi:\n10.1007\/s00259-013-2342-x\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3759_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.2967\/jnumed.109.065664","volume":"50","author":"H Minn","year":"2009","unstructured":"Minn H, Kauhanen S, Sepp\u00e4nen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915\u20138. doi:\n10.2967\/jnumed.109.065664\n\n.","journal-title":"J Nucl Med"},{"key":"3759_CR5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehofer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64\u201371.","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"3759_CR6","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","volume":"34","author":"B Beuthien-Baumann","year":"2007","unstructured":"Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-Omethyl- 6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34(10):1604\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3759_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.107.047720","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JWB, Plukke JTM, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524\u201331. doi:\n10.2967\/jnumed.107.047720\n\n.","journal-title":"J Nucl Med"},{"key":"3759_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","volume":"19","author":"M Beheshti","year":"2009","unstructured":"Beheshti M, P\u00f6cher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PETCT. Eur Radiol. 2009;19:1425\u201334. doi:\n10.1007\/s00330-008-1280-7\n\n.","journal-title":"Eur Radiol"},{"issue":"5","key":"3759_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/thy.2009.0342","volume":"20","author":"M Luster","year":"2010","unstructured":"Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20(5):527\u201333. doi:\n10.1089\/thy.2009.0342\n\n.","journal-title":"Thyroid"},{"issue":"4","key":"3759_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","volume":"36","author":"MC Marzola","year":"2010","unstructured":"Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET\/CT with (18)F-DOPA and (18)FFDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36(4):414\u201321. doi:\n10.1016\/j.ejso.2010.01.001\n\n.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"3759_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2967\/jnumed.111.094771","volume":"52","author":"S Kauhanen","year":"2011","unstructured":"Kauhanen S, Schalin-J\u00e4ntti C, Sepp\u00e4nen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855\u201363. doi:\n10.2967\/jnumed.111.094771\n\n.","journal-title":"J Nucl Med"},{"issue":"4","key":"3759_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Villani MF, Perotti G. deWaure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Gasomatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(4):569\u201380. doi:\n10.1007\/s00259-011-2031-6\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3759_CR13","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53(12):1863\u201371. doi:\n10.2967\/jnumed.112.105940\n\n.","journal-title":"J Nucl Med"},{"issue":"11","key":"3759_CR14","first-page":"6647","volume":"34","author":"A Sesti","year":"2014","unstructured":"Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R, et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Res. 2014;34(11):6647\u201354.","journal-title":"Anticancer Res"},{"issue":"10","key":"3759_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.acra.2012.05.008","volume":"19","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19(10):1290\u20139. doi:\n10.1016\/j.acra.2012.05.008\n\n.","journal-title":"Acad Radiol"},{"issue":"6","key":"3759_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"RT Kloos","year":"2009","unstructured":"Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565\u2013612. doi:\n10.1089\/thy.2008.0403\n\n.","journal-title":"Thyroid"},{"issue":"1","key":"3759_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181\u2013200. doi:\n10.1007\/s00259-009-1297-4\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3759_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cen.12515","volume":"81","author":"P Perros","year":"2014","unstructured":"Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1\u2013122. doi:\n10.1111\/cen.12515\n\n.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"3759_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000336977","volume":"1","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW, et al. European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5\u201314. doi:\n10.1159\/000336977\n\n.","journal-title":"Eur Thyroid J"},{"issue":"3","key":"3759_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000354537","volume":"2","author":"L Leenhardt","year":"2013","unstructured":"Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2(3):147\u201359. doi:\n10.1159\/000354537\n\n.","journal-title":"Eur Thyroid J"},{"issue":"1","key":"3759_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cpet.2013.08.013","volume":"9","author":"H Minn","year":"2014","unstructured":"Minn H, Kemppainen J, Kauhanen S, Forsback S, Sepp\u00e4nen M. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. PET Clin. 2014;9(1):27\u201336. doi:\n10.1016\/j.cpet.2013.08.013\n\n.","journal-title":"PET Clin"},{"issue":"6","key":"3759_CR22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00259-015-3227-y","volume":"43","author":"A Archier","year":"2016","unstructured":"Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, et al. 18F-DOPA PET\/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(6):1027\u201333. doi:\n10.1007\/s00259-015-3227-y\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3759_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ccr3.159","volume":"3","author":"AL Aziz","year":"2015","unstructured":"Aziz AL, Dierickx L, Courbon F, Ta\u00efeb D, Zerdoud S. (18)F-Fluorine-18-l-dihydroxyphenylalanine ((18)F-DOPA) positive isolated peritoneal carcinomatosis from a MENII-related medullary thyroid carcinoma. About an atypical metastatic site and utility of (18)F-FDOPA. Clin Case Rep. 2015;3(2):81\u20133. doi:\n10.1002\/ccr3.159\n\n.","journal-title":"Clin Case Rep"},{"issue":"6","key":"3759_CR24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1097\/RLU.0000000000001216","volume":"41","author":"JB Ruiz","year":"2016","unstructured":"Ruiz JB, Orr\u00e9 M, Cazeau AL. Henriques de Figueiredo B, Godbert Y. 18F-DOPA PET\/CT in Orbital Metastasis From Medullary Thyroid Carcinoma. Clin Nucl Med. 2016;41(6):e296\u20137. doi:\n10.1097\/RLU.0000000000001216\n\n.","journal-title":"Clin Nucl Med"},{"key":"3759_CR25","doi-asserted-by":"publisher","first-page":"324686","DOI":"10.1155\/2012\/324686","volume":"2012","author":"G Treglia","year":"2012","unstructured":"Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET Imaging in Recurrent Medullary Thyroid Carcinoma. Int J Mol Imaging. 2012;2012:324686. doi:\n10.1155\/2012\/324686\n\n.","journal-title":"Int J Mol Imaging"},{"issue":"4","key":"3759_CR26","doi-asserted-by":"publisher","first-page":"e8156","DOI":"10.5812\/ijem.8156","volume":"11","author":"E Skoura","year":"2013","unstructured":"Skoura E. Despicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4):e8156. doi:\n10.5812\/ijem.8156\n\n.","journal-title":"Int J Endocrinol Metab"},{"key":"3759_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00259-009-1204-z","volume":"37","author":"BG Conry","year":"2010","unstructured":"Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET\/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49\u201357. doi:\n10.1007\/s00259-009-1204-z\n\n.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3759_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MNM.0000000000000240","volume":"36","author":"ZG Ozkan","year":"2015","unstructured":"Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, et al. Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun. 2015;36(3):242\u201350. doi:\n10.1097\/MNM.0000000000000240\n\n.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"3759_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1967\/s002449910163","volume":"18","author":"K Tran","year":"2015","unstructured":"Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, et al. Gallium-68 Dotatate PET\/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015;18(1):19\u201324. doi:\n10.1967\/s002449910163\n\n.","journal-title":"Hell J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3759-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T05:17:28Z","timestamp":1514265448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3759-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3759-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}